Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL7245310 | 1.00 | MCHR1 (0.49) | MCHR1S1PR1HRH3LMNASLC6A4 | |
| SCHEMBL7333002 | 0.95 | MCHR1 (0.51) | MCHR1S1PR1HRH3LMNASLC6A4 | |
| Oxalic Acid SCHEMBL7320960 | 0.82 | S1PR1 (0.51) | MCHR1S1PR1HRH3LMNASLC6A4 | |
| Oxalic Acid SCHEMBL7320957 | 0.82 | S1PR1 (0.51) | MCHR1S1PR1HRH3LMNASLC6A4 | |
| Oxalic Acid SCHEMBL7331911 | 0.81 | S1PR1 (0.49) | MCHR1S1PR1HRH3LMNASIGMAR1 | |
| Oxalic Acid SCHEMBL7327873 | 0.81 | SLC6A4 (0.65) | S1PR1HRH3LMNASLC6A4SLC6A3 | |
| Oxalic Acid SCHEMBL7327867 | 0.81 | SLC6A4 (0.65) | S1PR1HRH3LMNASLC6A4SLC6A3 | |
| SCHEMBL7325847 | 0.77 | SLC6A4 (0.53) | S1PR1HRH3LMNASLC6A4SLC6A3 | |
| SCHEMBL7325843 | 0.77 | SLC6A4 (0.53) | S1PR1HRH3LMNASLC6A4SLC6A3 | |
| SCHEMBL7326600 | 0.75 | SLC6A4 (0.71) | S1PR1HRH3LMNASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534525-B1 | Method of using 2- substituted piperidine analogs as selectively active antagonist of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, | WARNER-LAMBERT & COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-6124317-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0629190-A1 | COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-21 | — | — | EP | disclosed |
| WO-1993015052-A1 | COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |